Sign in
Not yet taking people in IsraelPhase 3

Long-term study of lerodalcibep in children and teens with inherited high cholesterol

Tests lerodalcibep over 3 years in children and teens with familial hypercholesterolemia.

Key facts

Who runs it
LIB Therapeutics LLC
Where
Jerusalem, IsraelSee the siteAlso in 4 other countries, 4 sites
Registry title
Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia
Status
Not yet recruiting
Phase
Phase 3
People taking part
150 people, planned
Starts
20 Jan 2027
Expected to end
31 Dec 2031
Type of study
Interventional
Treatments tested
  • Lerodalcibep
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teens aged 6 to 17 with inherited high cholesterol (heterozygous familial hypercholesterolemia) who finished the earlier 24-week base trial (LIB003-008). They get monthly lerodalcibep injections for 3 years.

Age
6 to 17 years (from 6 to less than 18 years old) at the first screening visit of the LIB003-008 study
Sex
All sexes
Disease stage
Heterozygous familial hypercholesterolemia (HeFH, inherited high cholesterol)
Earlier treatment
Must have finished the LIB003-008 study, with the last dose of study drug at Week 20 and the Week 24 visit done. Must be on a stable diet and cholesterol-lowering pills (statins, ezetimibe, bile-acid sequestrants) or a mix of them. Mipomersen, lomitapide and gemfibrozil are not allowed.

Main reasons for not taking part

  • Any past or current illness that the investigator thinks could make taking part unsafe or affect the results
  • Pregnant or breastfeeding, or sexually active and not willing to use very reliable contraception
  • Positive urine pregnancy test at the last screening visit
  • Cannot attend the visits or procedures the trial requires
  • Drug or alcohol abuse during the LIB003-008 study

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Provision of written and signed informed consent/assent of the LIB003-016 trial prior to any study-specific procedure
  • Completion of the LIB003-008 study having received the last dose of study drug at Week 20 and completed the Week 24 visit
  • Male or female, 6 to 17 years of age (defined as from 6 to less than 18 years of age), at the first Screening Visit of the LIB003-008 study
  • Weight of >18 kg (40 lbs) and BMI <17 and >42 kg/m2
  • On stable diet and lipid-lowering oral drug therapy (statins, ezetimibe, bile-acid sequestrants) or combinations thereof (excluded oral lipid-lowering agents are include mipomersen, lomitapide, and gemfibrozil)

Who cannot take part

  • History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator, which in the Investigator's opinion, would not be suitable for the study from a patient safety consideration or could interfere with the results of the study
  • Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception during the study and until 60 days after last dose of study drug, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit
  • A history, during the LIB003-008 study of prescription drug abuse, illicit drug use, or alcohol abuse according to medical history
  • Patients who cannot be available for Protocol-required study visits or procedures, to the best of the patient's and Investigator's knowledge
  • Have any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 17 years old?

Where in Israel

Also in 4 other countries, 4 sites

  • Haddassah Medical CenterJerusalem, IsraelContact: Kate Caldwell, BS MT(ASCP)Not yet recruiting

About the trial

What the trial wants to find out

The goal is to assess the long term efficacy (LDL cholesterol reduction) and safety over 3 years of lerodalcibep (Lerochol) SC 300 mg QM administered by auto-injector (AI)/pre-filled pen (PFP) in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins who completed the 24 week placebo controlled base trial.

Read full original descriptionShow less

The main question[s] it aims to answer are:

How effective is Lerochol in maintaining LDL cholesterol reductions over years? How well is it tolerated and are there any safety concerns?

Participants will visit the clinic every month for 3 months and then home dosed with clinic visits every 3 months. They will undergo periodic physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.

The group in the trial

  • LerodalcibepTreatment being tested

    lerodalcibep 300 mg monthly

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Open Label Phase 3b Study to Evaluate the Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia (LIBerate-Kids OLE)
Plain-language title
Long-term study of lerodalcibep in children and teens with inherited high cholesterolGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07775339, who can take part
Record updated
25 August 2026